Data on new drugs and biologics reviewed and approved by the FDA's Center for Drug Evaluation and Research from 2011 to 2015. Used for Professor Carpenter's presentation to the U.S. Food and Drug Administration on July 15, 2015, on the Prescription Drug User Fee Act of 2017
This dataset replicates the findings from Stakeholder Participation in Policymaking: Evidence from M...
The data and programs replicate tables and figures from "Who Profits from Patents? Rent-Sharing at I...
The programs replicate tables and figures from "Who Becomes an Inventor in America? The Importance o...
Replication data for: "The Market for High-Quality Medicine: Retail Chain Entry and Drug Quality in ...
Objective: To evaluate the accuracy of a 2015 cross-sectional analysis published in the BMJ Open whi...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...
Replication Data for: "The Local Influence of Pioneer Investigators on Technology Adoption: Evidence...
The data and programs replicate tables and figures from "Uniform Pricing in U.S. Retail Chains", by ...
All FDA labels and extraction sheets to support our paper, Desai et al. "Reporting of drug benefit i...
The data file contains, among other details, sponsor, study ID, registration timing, and results rep...
This is the replication data and code for the paper "Diagnostic Ability and Inappropriate Antibiotic...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...
A total of 45 new chemical entities had been approved in 1997 by the Food and Drug Administration (F...
Replication data for: "Subsidies and Structure: The Lasting Impact of the Hill-Burton Program on the...
Identification of adverse drug reactions (ADRs) during the post-marketing phase is one of the most i...
This dataset replicates the findings from Stakeholder Participation in Policymaking: Evidence from M...
The data and programs replicate tables and figures from "Who Profits from Patents? Rent-Sharing at I...
The programs replicate tables and figures from "Who Becomes an Inventor in America? The Importance o...
Replication data for: "The Market for High-Quality Medicine: Retail Chain Entry and Drug Quality in ...
Objective: To evaluate the accuracy of a 2015 cross-sectional analysis published in the BMJ Open whi...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...
Replication Data for: "The Local Influence of Pioneer Investigators on Technology Adoption: Evidence...
The data and programs replicate tables and figures from "Uniform Pricing in U.S. Retail Chains", by ...
All FDA labels and extraction sheets to support our paper, Desai et al. "Reporting of drug benefit i...
The data file contains, among other details, sponsor, study ID, registration timing, and results rep...
This is the replication data and code for the paper "Diagnostic Ability and Inappropriate Antibiotic...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...
A total of 45 new chemical entities had been approved in 1997 by the Food and Drug Administration (F...
Replication data for: "Subsidies and Structure: The Lasting Impact of the Hill-Burton Program on the...
Identification of adverse drug reactions (ADRs) during the post-marketing phase is one of the most i...
This dataset replicates the findings from Stakeholder Participation in Policymaking: Evidence from M...
The data and programs replicate tables and figures from "Who Profits from Patents? Rent-Sharing at I...
The programs replicate tables and figures from "Who Becomes an Inventor in America? The Importance o...